➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Baxter
Johnson and Johnson
Colorcon
Boehringer Ingelheim
AstraZeneca
Moodys

Last Updated: August 6, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for Losmapimod

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

What is the development status for investigational drug Losmapimod?

Losmapimod is an investigational drug.

There have been 11 clinical trials for Losmapimod. The most recent clinical trial was a Phase 3 trial, which was initiated on June 1st 2014.

The most common disease conditions in clinical trials are Acute Coronary Syndrome, Pulmonary Disease, Chronic Obstructive, and Muscular Dystrophy, Facioscapulohumeral. The leading clinical trial sponsors are GlaxoSmithKline, Fulcrum Therapeutics, and The TIMI Study Group.

There are nine US patents protecting this investigational drug and eighty-seven international patents.

Recent Clinical Trials for Losmapimod
TitleSponsorPhase
Efficacy and Safety of Losmapimod in Treating Subjects With Facioscapulohumeral Muscular Dystrophy (FSHD) With Open-Label Extension (OLE)Fulcrum TherapeuticsPhase 2
Efficacy and Safety of Losmapimod in Subjects With Facioscapulohumeral Muscular Dystrophy (FSHD)Fulcrum TherapeuticsPhase 2
Evaluation of Safety, Tolerability, and Changes in Biomarker and Clinical Outcome Assessments of Losmapimod for FSHD1Fulcrum TherapeuticsPhase 2

See all Losmapimod clinical trials

Clinical Trial Summary for Losmapimod

Top disease conditions for Losmapimod
Top clinical trial sponsors for Losmapimod

See all Losmapimod clinical trials

US Patents for Losmapimod

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Losmapimod   Start Trial P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD Fulcrum Therapeutics, Inc. (Cambridge, MA)   Start Trial
Losmapimod   Start Trial Nicotinamide derivatives useful as p38 inhibitors. SmithKline Beecham Corporation (Philadelphia, PA)   Start Trial
Losmapimod   Start Trial Nicotinamide derivatives useful as p38 inhibitors SmithKline Beecham Corporation (Philadelphia, PA)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Johnson and Johnson
Colorcon
Boehringer Ingelheim
AstraZeneca
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.